Confirmed 6-Month Disability Improvement and Worsening Correlate With Long-term Disability Outcomes in Alemtuzumab-Treated Patients With Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies
mediaposted on 17.06.2021, 07:55 by Adis journals on behalf of, Samuel F. Hunter, Rany A. Aburashed, Raed Alroughani, Andrew Chan, Dominique Dive, Sarah Eichau, Daniel Kantor, Ho Jin Kim, Jan Lycke, Richard A.L. Macdonell, Carlo Pozzilli, Thomas Scott, Basil Sharrack, Heinz Wiendl, Luke Chung, Nadia Daizadeh, Darren P. Baker, Patrick Vermersch, on behalf of the CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators
Article full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.